Navigation Links
BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
Date:8/9/2012

LYNBROOK, N.Y., Aug. 9, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the second quarter ended June 30, 2012 and provided a corporate update.

"We are very pleased with the clinical and regulatory progress of XIAFLEX in recent months and are excited about the upcoming anticipated milestones for the remainder of this year," reflected Thomas L. Wegman, President of BioSpecifics. "We announced positive top-line results from Auxilium's two IMPRESS Phase III clinical trials of XIAFLEX for Peyronie's disease in June and expect Auxilium to submit a sBLA filing by the end of the year. BioSpecifics also initiated two Phase II clinical trials in canine and human lipomas and we anticipate we will complete enrollment for both of these studies in the first half of 2013. Additionally, XIAFLEX was recently approved in Canada for Dupuytren's contracture and Auxilium's partner Actelion expects to file for approval in Australia, Brazil and Mexico by the end of 2012."

Second Quarter 2012 Financial ResultsBioSpecifics reported a net income of $0.7 million for the second quarter ended June 30, 2012, or $0.11 per basic and $0.10 per diluted share, compared to a net income of $2.6 million, or $0.40 per basic and $0.36 per diluted share, for the same period in 2011.

Total revenue for the second quarter of 2012 was $2.6 million, compared to $5.0 million for the same period in 2011.

Royalty, mark-up on cost of goods sold, and earn-out revenues for the second quarter ended June 30, 2012 were $2.5 million, compared to $1.7 million for the same period in 2011. Royalty and mark-up on cost of goods sold revenues recognized under the Comp
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
2. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
3. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
4. Life Technologies Announces $750 Million Share Repurchase Program
5. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
6. Life Technologies Moving "Off the Grid" with Clean Energy Fuel Cells
7. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
8. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
9. Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology for Proteomic Applications in Research, Applied and Clinical Markets
10. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
11. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... IRVINE, Calif. , Feb. 26, 2015 /PRNewswire/ ... of age-defying aesthetic products for skin and hair ... Market Relations as agency of record for investor ... continues to improve our distribution, sales and diversification ... activities to current and prospective shareholders," stated Ali ...
(Date:2/26/2015)... Innovation is more urgent than ever. ... of the world and transforming global markets in ... to health care, disruption is constantly underway. , ... trends shake the foundations of established business models, ... to survive the next wave of mega-change. , ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ... with reovirus are available today on the ... http://www.aacr.org, and on the Oncolytics,website ... scheduled to,be delivered at the AACR Annual ...
... 13 Silence Therapeutics plc,(AIM: SLN) today announces ... development of a range of novel approaches for ... Silence Therapeutics, leading,expertise in the delivery of siRNA ... delivery of siRNA in vivo using its,proprietary AtuPLEX ...
... Today, March 13, 2008 at 11:00 AM ET -, ... reported results for the year and quarter ended,December 31, 2007. ... to $273,000 for the year ended December 31, 2006.,Revenues for ... the same period in 2006., The net loss for ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting 3Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 2Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 4Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 5
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... farm to the insects which blight them mankind has ... species while falling victim to others. In Biological Diversity: ... the subject of biodiversity through the species that humans ... authors selected 18 such organisms and have used them ...
... including several from the Smithsonian Institution, discovered that leaves ... more veins per unit area than leaves ever had ... water available to the leaves, making it possible for ... better plumbing system may also have radically altered water ...
... Techne Corporation,s (NASDAQ: TECH ) consolidated pretax ... increased 9.5% to $45.4 million compared with $41.4 million ... a result of increased sales and foreign exchange transaction ... expenses. For the nine months ended March 31, 2011, ...
Cached Biology News:First rainforests arose when plants solved plumbing problem 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2011 7
... BacMagic™ DNA Kit provides a positive selection ... recombinant protein expression in insect cells. The ... generating recombinant baculoviruses by eliminating the time-consuming ... is an AcNPV genome with a portion ...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: